Skip to main
PLRX

PLRX Stock Forecast & Price Target

PLRX Analyst Ratings

Based on 3 analyst ratings
Hold
Strong Buy 0%
Buy 33%
Hold 67%
Sell 0%
Strong Sell 0%

Bulls say

Pliant Therapeutics Inc. possesses a robust scientific foundation and an experienced management team, which may enhance its competitive positioning in the biopharmaceutical sector. The company's lead candidate, PLN-101095, has demonstrated promising efficacy and safety signals in Phase I trials, revealing significant increases in IFN-γ levels among responders. Furthermore, Pliant’s innovative integrin-targeted delivery platform and the planned expansion into Phase 1b trials based on positive results indicate a strategic pathway for potential value creation in the treatment of solid tumors and idiopathic pulmonary fibrosis.

Bears say

Pliant Therapeutics Inc faces significant risks related to potential clinical trial failures and setbacks, particularly given the historical challenges in developing integrin inhibitors for conditions like idiopathic pulmonary fibrosis (IPF). The company’s strategic reliance on its lead product candidate, PLN-101095, and its pipeline of integrin-based therapies exposes it to high regulatory risks, as evolving requirements from regulatory bodies could impact trial outcomes and market approval. Additionally, a decline in Pliant's share price is attributed to an updated cash position and increased share counts, indicating financial strain that could hinder its development efforts moving forward.

PLRX has been analyzed by 3 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 33% recommend Buy, 67% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Pliant Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Pliant Therapeutics (PLRX) Forecast

Analysts have given PLRX a Hold based on their latest research and market trends.

According to 3 analysts, PLRX has a Hold consensus rating as of Apr 21, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $2.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $2.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Pliant Therapeutics (PLRX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.